Table 2.

Characteristics of the Norwegian MFS cohort from the first investigations in 2003–2004 to follow‐up in 2014–2015

	2003–2004 n (%)	2014–2015 n (%)
FBN1 mutation	55 (87)	58 (92)
Patients on β‐blockers and/or other antihypertensive agents	32 (51)	46 (73)
Patients with aortic surgery before inclusion in 2003	24 (38)
Patients with new cardiovascular events		32 (51)
Patients with aortic surgery during follow‐up		24 (38)
Total patients who have undergone aortic surgery		37 (59)

N = 63 (47 survivors and 16 deceased), 42 (67%) women.